Stockscreener 앱 받기
19.90
5.06%
-1.06
전일 마감가:
$20.96
열려 있는:
$21.2
하루 거래량:
1.18M
Relative Volume:
0.65
시가총액:
$2.47B
수익:
$181.74M
순이익/손실:
$-599.49M
주가수익비율:
-3.9721
EPS:
-5.01
순현금흐름:
$-604.32M
1주 성능:
-0.25%
1개월 성능:
+0.71%
6개월 성능:
-21.16%
1년 성능:
-31.80%
1일 변동 폭
$19.88
$21.30
1주일 범위
$19.88
$21.30
52주 변동 폭
$17.05
$36.72
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
명칭
Arrowhead Pharmaceuticals Inc
전화
626-696-4702
주소
177 E COLORADO BLVD, PASADENA, CA
ARWR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
19.90 | 2.47B | 181.74M | -599.49M | -604.32M | -5.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-05 | 개시 | Goldman | Neutral |
| 2023-12-04 | 개시 | BofA Securities | Buy |
| 2023-09-19 | 개시 | Citigroup | Neutral |
| 2023-07-21 | 개시 | TD Cowen | Outperform |
| 2023-05-12 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | 개시 | SMBC Nikko | Outperform |
| 2023-04-12 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2022-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-05-11 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | 재개 | Goldman | Buy |
| 2021-08-06 | 재확인 | Chardan Capital Markets | Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-21 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-11-19 | 개시 | Citigroup | Buy |
| 2020-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2020-05-08 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-04-15 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | 개시 | Goldman | Neutral |
| 2020-01-21 | 개시 | SVB Leerink | Underperform |
| 2019-12-13 | 개시 | Oppenheimer | Perform |
| 2019-11-29 | 재확인 | Chardan Capital Markets | Buy |
| 2019-11-27 | 재확인 | B. Riley FBR | Buy |
| 2019-11-25 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | 재확인 | Chardan Capital Markets | Buy |
| 2019-10-03 | 개시 | Robert W. Baird | Outperform |
| 2018-09-07 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | 재확인 | Chardan Capital Markets | Buy |
| 2018-08-08 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-07-02 | 재확인 | Chardan Capital Markets | Buy |
모두보기
Arrowhead Pharmaceuticals Inc 주식(ARWR)의 최신 뉴스
Arrowhead Pharmaceuticals (ARWR): Among the Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
12 Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions (NASDAQ:ARWR) - Seeking Alpha
Zacks Small Cap Has Pessimistic Outlook of ARWR Q2 Earnings - MarketBeat
Analysts Offer Predictions for ARWR Q2 Earnings - MarketBeat
Arrowhead Pharmaceuticals' SWOT analysis: RNAi pioneer's stock poised for potential breakthrough By Investing.com - Investing.com South Africa
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Receives "Buy" Rating from B. Riley - MarketBeat
Arrowhead Pharmaceuticals' SWOT analysis: RNAi pioneer's stock poised for potential breakthrough - Investing.com
Arrowhead Pharmaceuticals' (ARWR) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Guidewire Software set to join S&P MidCap 400; Arrowhead Pharmaceuticals to join S&P SmallCap 600 - MSN
Leerink Partnrs Analysts Raise Earnings Estimates for ARWR - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Down 5%What's Next? - MarketBeat
Arrowhead and Sarepta close $500 million licensing deal - MSN
When (ARWR) Moves Investors should Listen - Stock Traders Daily
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Earns Outperform Rating from Royal Bank of Canada - MarketBeat
Arrowhead sees potential $2-3B annual sales for plozasiran in SHTG market by 2026 - MSN
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
B. Riley Adjusts Price Target on Arrowhead Pharmaceuticals to $38 From $51, Keeps Buy Rating - Marketscreener.com
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2025 Earnings Call Transcript - MSN
Arrowhead Pharmaceuticals' (ARWR) "Buy" Rating Reiterated at Chardan Capital - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Announces Quarterly Earnings Results, Misses Expectations By $0.97 EPS - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Issues Quarterly Earnings Results - MarketBeat
Arrowhead Pharmaceuticals: Promising Pipeline Amidst Cautious Financial Outlook Warrants Hold Rating - TipRanks
Arrowhead Pharmaceuticals IncOn February 10 - Smartkarma
Arrowhead Pharmaceuticals (ARWR) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Purchased by abrdn plc - MarketBeat
Arrowhead Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - TipRanks
Earnings call transcript: Arrowhead Pharma misses Q1 2025 forecasts By Investing.com - Investing.com Nigeria
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap Down After Earnings Miss - MarketBeat
Arrowhead Pharmaceuticals Inc (ARWR) Q1 2025 Earnings Call Highlights: Strategic Collaborations ... - Yahoo Finance
Arrowhead Pharmaceuticals Inc (ARWR) Q1 2025 Earnings Call Highl - GuruFocus.com
Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results - BioSpace
Arrowhead Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Arrowhead Pharmaceuticals: Strategic Licensing Deal and Upcoming Drug Launch Drive Buy Rating - TipRanks
Earnings call transcript: Arrowhead Pharma misses Q1 2025 forecasts - Investing.com
Arrowhead Pharmaceuticals Inc. (ARWR) reports earnings - Quartz
Arrowhead Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Arrowhead Pharmaceuticals Fiscal Q1 Loss Widens, Revenue Declines -- Shares Down After Hours - Marketscreener.com
Earnings Flash (ARWR) Arrowhead Pharmaceuticals Reports Q1 Revenue $2.5M -February 10, 2025 at 04:16 pm EST - Marketscreener.com
ARROWHEAD PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Arrowhead Pharmaceuticals Q1 2025 Earnings Preview - MSN
Arrowhead and Sarepta close $500 million licensing deal By Investing.com - Investing.com Australia
ARWR Seals Mega-Deal: $825M Cash Infusion Plus Billions in Potential Milestone Payments - StockTitan
Cautious On Arrowhead Pharmaceuticals' FDA NDA Acceptance Due To Valuation Concerns - Seeking Alpha
Arrowhead Pharmaceuticals Inc (ARWR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.27%
3.05%
자본화:
|
볼륨(24시간):